Dong-Yeon Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dong-Yeon Han has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Hun-Jun Park
Department of biomedicine and health sciences, The Catholic University of Korea, Seoul 06591, Republic of Korea
3 shared publications - Donghyun Lee
Department of Medical Life Sciences and Department of Medical Sciences (Graduate School), College of Medicine, The Catholic University of Korea 1 , 222 Banpo-daero, Seocho-gu, Seoul 06591
1 shared publication - Heebeom Koo
Department of Medical Life Sciences and Department of Medical Sciences (Graduate School) College of Medicine The Catholic University of Korea Seoul Republic of Korea
1 shared publication Hyejin Hong
1 shared publication- Hyo-Suk Ahn
Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Hyuk Sang Yoo
Kangwon National University
1 shared publication
Latest Publications
- Open Access
- 1 February 2027
- Published by KEAI Publishing in Bioactive Materials
- Vol. 68, 814-834
Click chemistry-modified cardiomyocytes enhance cardiac contractility and prevent remodeling in ischemia-reperfusion injured hearts
- 1 February 2027
- Published by KEAI Publishing in Bioactive Materials
- Vol. 68, 814-834
Open AccessClick chemistry-modified cardiomyocytes enhance cardiac contractility and prevent remodeling in ischemia-reperfusion injured hearts
- 13 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124544
In situ bioorthogonal anchoring of stem cells to conductive nanofibrils for enhanced myocardial infarction repair
- 13 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124544
In situ bioorthogonal anchoring of stem cells to conductive nanofibrils for enhanced myocardial infarction repair
- Top Cited PapersOpen Access
- 24 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2106
Myocardial Ischemia–Reperfusion Injury—Mechanistic Insights and Novel Therapeutics
Myocardial ischemia–reperfusion (I/R) injury remains a major contributor to infarct expansion and adverse cardiac remodeling despite advances in timely reperfusion therapy. Although restoration of blood flow is essential for myocardial salvage, the abrupt transition from ischemia to reperfusion paradoxically exacerbates cardiomyocyte injury through profound metabolic, ionic, and mitochondrial disturbances. Reperfusion should be viewed not simply as restoration of blood flow, but as a critical biological transition that converts ischemic stress into a self-amplifying injury network. Reperfusion induces excessive reactive oxygen species generation, calcium overload, endothelial barrier disruption, and dysregulated innate immune activation, which converge on mitochondrial dysfunction and diverse forms of cell death, including apoptosis, necroptosis, pyroptosis, and ferroptosis. Emerging evidence highlights that these pathological processes are tightly interconnected through damage-associated molecular pattern signaling, microvascular leakage, and inflammatory amplification, underscoring the limitations of single-target therapeutic approaches. This review summarizes the molecular and cellular mechanisms underlying myocardial I/R injury with a particular focus on oxidative stress, immune modulation, vascular integrity, and ferroptosis. We further discuss current and emerging cardioprotective strategies, including antioxidant therapies, modulation of neutrophil recruitment, microvascular leakage blockade, and anti-ferroptotic interventions. Finally, we address key translational challenges and future perspectives for developing integrated cardioprotective therapies aimed at improving clinical outcomes in acute myocardial infarction.
- 24 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2106
Top Cited PapersOpen AccessMyocardial Ischemia–Reperfusion Injury—Mechanistic Insights and Novel Therapeutics
Myocardial ischemia–reperfusion (I/R) injury remains a major contributor to infarct expansion and adverse cardiac remodeling despite advances in timely reperfusion therapy. Although restoration of blood flow is essential for myocardial salvage, the abrupt transition from ischemia to reperfusion paradoxically exacerbates cardiomyocyte injury through profound metabolic, ionic, and mitochondrial disturbances. Reperfusion should be viewed not simply as restoration of blood flow, but as a critical biological transition that converts ischemic stress into a self-amplifying injury network. Reperfusion induces excessive reactive oxygen species generation, calcium overload, endothelial barrier disruption, and dysregulated innate immune activation, which converge on mitochondrial dysfunction and diverse forms of cell death, including apoptosis, necroptosis, pyroptosis, and ferroptosis. Emerging evidence highlights that these pathological processes are tightly interconnected through damage-associated molecular pattern signaling, microvascular leakage, and inflammatory amplification, underscoring the limitations of single-target therapeutic approaches. This review summarizes the molecular and cellular mechanisms underlying myocardial I/R injury with a particular focus on oxidative stress, immune modulation, vascular integrity, and ferroptosis. We further discuss current and emerging cardioprotective strategies, including antioxidant therapies, modulation of neutrophil recruitment, microvascular leakage blockade, and anti-ferroptotic interventions. Finally, we address key translational challenges and future perspectives for developing integrated cardioprotective therapies aimed at improving clinical outcomes in acute myocardial infarction.